WebAug 27, 2024 · Adverse events that emerged during treatment were generally mild to moderate in severity, and permanent discontinuation of tafamidis or placebo as a result of adverse events was less common in the ...
VYNDAQEL® OR VYNDAMAX™ Adverse Reactions …
WebTo report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov ... During clinical trials, two patients accidentally … WebAdverse Reactions. In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with VYNDAQEL® (tafamidis meglumine) was similar to placebo. Specific Populations Pregnancy: Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to a pregnant woman. new hope agency
tafamidis Uses, Side Effects, Dosage & Interactions - eMedicineHealth
Along with its needed effects, tafamidis may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention. Check with your doctor immediatelyif any of the following side effects occur while taking tafamidis: See more Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. Some side effects may not be … See more WebFeb 25, 2024 · Tell all of your health care providers that you take this medicine (tafamidis). This includes your doctors, nurses, pharmacists, and dentists. You may need to use birth … WebOct 17, 2016 · Tafamidis. DrugBank Accession Number. DB11644. Background. Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives 1 developed by FoldRX. 4 Tafamidis is structurally similar to diflusinal. 4. Tafamidis was granted an EMA market authorisation on 16 November 2011 6 and FDA approval on 3 May 2024. 7. new hope african methodist episcopal church